Clinical Trial Details

EORTC-06061

Back to Clinical Trials Database

Clofarabine in combination with a standard remissioninduction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS) : a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial)

Study documentation Publications

Trial Status All trial activities ended
Dates Date of activation: 21-Nov-2008
Date Step1 close: 16-May-2013
Data management at EORTC Yes
Design Phase 1-2
Randomized open label
Targeted Sample size EORTC Groups: 77 - All Groups: 90
Treatment Clofarabine, Cytarabine, Idarubicin
Study Staff
Type of cancer
Participating groups EORTC Leukemia Group
Gruppo Italiano Malattie Ematologiche dell'Adulto
Protocol summary http://clinicaltrials.gov/ct/show/NCT00838240
NCT number NCT00838240
EudraCT 2006-004912-28